Superiority of ATG induction therapy in lung transplant recipients with cystic fibrosis  by Jaksch, P. et al.
S68 7. Pulmonology
271* Superiority of ATG induction therapy in lung transplant
recipients with cystic ﬁbrosis
P. Jaksch1, J. Ankersmit1, B. Zweytick1, C. Aigner1, G. Lang1, A. Hoda1,
M. Keplinger1, W. Klepetko1. 1Medical Univerity of Vienna, Thorcic Surgery,
Vienna, 1090, Austria
Objective: The use of induction therapy after lung transplantation is discussed
controversly. Without use of any induction agent the incidence of acute rejection
episodes within the ﬁrst postoperative months is still higher after LuTX compared
to other solid organ transplantations.
We therefore hypothesised that induction therapy with rabbit-antithymocyte-globulin
(ATG) used in patients with CF would reduce acute rejection episodes in the
early postoperative course. We retrospectively analysed the ﬁles of all CF patients
transplanted between 1999–2007.
Methods: In a 9 year period between 1999–2007 93 patients with CF underwent
TX. Demographics: m/f = 42/51 (45%/55%), 89 (96%) received a DLuTX, 2 (2%)
a HLTX and 2 (2%) a SLuTX.
In 58 patients (62%) (group A) induction therapy with ATG was administered, 6
pats (6%) received Daclizumab (group B) and in 29 (32%) cases no induction agent
was (group B) used.
Results: Patients who received ATG (group A) as induction had 1, 3 and 5 year
survival of 95%, 93% and 86%, patients who received Dac (group B) or no induction
agent (group B) had a 1, 3 and 5 year survival of 66%, 65% and 65% (log rank
group A vs. group B p< 0.05).
The use of induction therapy with ATG compared to no induction therapy or Dac
resulted in fewer episodes of AR >grade A1 within the ﬁrst 100days post-transplant
(p< 0.05).
Conclusions: The use of ATG as an induction agent demonstrated excellent results
in regard to freedom from AR episodes and long-term survival compared to no
induction or induction therapy with Daclizumab. A signiﬁcant lower rate of deaths
due to infectious complications in the ATG group accounts for this improvement
of survival.
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CT is more sensitive than pulmonary function tests (PFTs) to track progression of
CF lung disease. Whether BE and air trapping (AT) on CT correlate with respiratory
tract exacerbations rate (RTE-R) an established outcome parameter is unknown.
Aim: To establish predictive value of BE and AT regarding RTE-R.
Methods: Inclusion criteria: children; CF;  1 routine bi-annual CT and  1PFT;
2 years follow up. RTE deﬁned as course of intravenous antibiotics. CT scans
were de-identiﬁed, randomized and scored (Brody-II) by 2 observers, assessing
BE, airway wall thickening, mucus, opacities and AT. CT component scores and
PFT parameters were divided in 4 categories with increasing degree of abnormality.
Analysis: uni- and multivariate Poisson models for exacerbation counts; intraclass
correlation coefﬁcients (ICC); Bland-Altman plots.
Results: 116 children (55M, 61F), contributed 171 CTs (61 patients 1CT, 55 2CTs).
Median (range) age and FEV1 12(5−20) years and 90(23–132)%pred. ICC range
0.61−0.99. Number of exacerbations was 156 in 335 person years. Signiﬁcant
correlations were found between CT scores (except AT), PFT parameters and
RTE-R. BE and FEV1 were strongest predictors for RTE-R. RTE-R ratios for
categories 2−4 relative to reference category 1 were for BE 1.2 (0.4−3.7, p = 0.81),
4.6 (1.7−12.6, p = 0.003) and 7.8 (3.0−20.1, p< 0.001) and for FEV1 1.2 (95% CI
0.5−2.9, p = 0.62), 2.9 (1.3−6.5, p = 0.007) and 5.9 (2.5−13.7, p< 0.001).
Conclusions: Bronchiectasis on chest CT is a strong predictor of respiratory tract
exacerbations in CF.
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Background: CT scans are used to assess structural lung disease in CF, however
data on disease progression in infants and preschool children are lacking. Aim: To
assess longitudinal changes in CT-detected structural lung disease in infants and
preschool children with CF.
Methods: Paired CT scans 1 year apart were obtained from 103 infants and
preschool children (mean age 2.5 years at initial scan and 3.5 years at second scan)
with 3 evenly spaced slices at end-inspiration and 3 slices at end-expiration to
represent the left and right upper, middle and lower zones. Each zone was assessed
for the presence (0 = absent, 1 = present) and the extent of the presence (1 = less
than 50%, 2 =more than 50%) of bronchial dilatation, peribronchial thickening and
air trapping.
Results: Bronchial dilatation was detected in 29% of initial scans and 68% of
second scans; peribronchial thickening in 62% and 92%, respectively; and air
trapping in 66% and 83%, respectively. Average extent of bronchial dilatation
increased from 1.2 to 2.3; peribronchial thickening from 3.3 to 5.3; and air trapping
from 2.5 to 3.5. When present at the initial scan, bronchial dilatation persisted in
77% of second scans (n = 30); peribronchial thickening in 97% (n = 64); and air
trapping in 93% (n = 68).
Conclusion: Early structural lung disease is common and progressive in the infant
and preschool population.
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We report on a 35-year-old patient with CF. The diagnose was made by sweat
test (Genotype R34P/1078delT). The patient is chronically infected with Pseu-
domonas aeruginosa. The treatment consists of an inhalation with hypertonic
saline plus Salbutamol, Dornase alfa, Tobramycin and medication with pancreatic
enzymes, Azithromycin and vitamins. The patient presented with symptoms of
an airway infection, thoracic pain and hemoptysis. An intravenous (i.v.) antibiotic
treatment with Tobramycin and Ceftazidim resulted in no signiﬁcant improvement
of health, the change of treatment to Fosfomycin and Aztreonam had no effect
as well. Laboratory tests revealed no increased infectious parameters. In the
thorax CT scan double sided inﬁltrates were seen. The bronchoalveolar lavage
detected 99% of granulocytes and 1% macrophages. Microbiological tests showed
copious Pseudomonas aeruginosa and Scedosporium apiospermum. Tuberculous,
non-tuberculous mycobacteria, Nocardia and Pneumocystis jiroveci were excluded.
We hypothesize that the inﬁltrates in the CT scan were due to the Scedosporium
detected in the sputum. Antifungal treatment with Caspofungin i.v. and Posaconazol
p.o. resulted in improvement of lung function and physical capicity. The succes-
sional CT scan showed no inﬁltrates.
Discussion: In case of pulmonary exacerbations the microbiological evidence of
bacteria such as Pseudomonas aeruginosa constitutes a distinct therapeutical indi-
cation. Whether the evidence of Scedosporium necessitates an antifungal treatment
or whether they are responsible for an pulmonary degregation is not deﬁnitely clear.
Our patient had a beneﬁt from the anitfungal treatment. As seen in this patient for
the duration of treatment no explicit recommendations can be made.
